Evidence map›Paper›PMID 36980692›Full record

ArticleCancers2023

Adoptive Cell Therapy in Hepatocellular Carcinoma: A Review of Clinical Trials.

Muhammet Ozer, Suleyman Yasin Goksu, Baran Akagunduz, Andrew George, Ilyas Sahin

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

Muhammet OzerDepartment of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-9579-1372
Suleyman Yasin GoksuDivision of Hematology and Oncology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0001-9453-342X
Baran AkagunduzDepartment of Medical Oncology, School of Medicine, Erzincan Binali Yildirim University, Erzincan 24100, Turkey.ORCID 0000-0002-4979-3123
Andrew GeorgeLaboratory of Translational Oncology and Experimental Cancer Therapeutics, The Warren Alpert Medical School, Brown University, Providence, RI 02915, USA.
Ilyas SahinDivision of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, FL 32608, USA.ORCID 0000-0003-2070-9319
Brown University · USErzincan Binali Yıldırım University · TRHarvard University · USThe University of Texas Southwestern Medical Center · USUniversity of Florida Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Immune checkpoint inhibitors (ICIs) have become the new reference standard in first-line HCC treatment, replacing tyrosine kinase inhibitors (TKIs) such as sorafenib. Many clinical trials with different combinations are already in development to validate novel immunotherapies for the treatment of patients with HCC. Adoptive cell therapy (ACT), also known as cellular immunotherapy, with chimeric antigen receptors (CAR) or gene-modified T cells expressing novel T cell receptors (TCR) may represent a promising alternative approach to modify the immune system to recognize tumor cells with better clinical outcomes. In this review, we briefly discuss the overview of ACT as a promising treatment modality in HCC, along with recent updates of ongoing clinical trials.

Indexed as

adoptive cell therapychimeric antigen receptorclinical trialshepatocellular carcinoma (HCC)immunotherapyT cell receptor

Identifiers

PMID36980692
PMCPMC10046758
OpenAlexW4327737557

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read3
identifiers read15
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.